|
|
???tair.name??? >
???browser.page.title.author???
|
"su w c"???jsp.browse.items-by-author.description???
Showing items 6-15 of 419 (42 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
| 國立成功大學 |
2023 |
Polygenic Risk Score, Environmental Tobacco Smoke, and Risk of Lung Adenocarcinoma in Never-Smoking Women in Taiwan
|
Blechter, Blechter B.;Chien, L.-H.;Chen, T.-Y.;Chang, I.-S.;Choudhury, P.P.;Hsiao, C.-F.;Shu, X.-O.;Wong, J.Y.Y.;Chen, K.-Y.;Chang, G.-C.;Tsai, Y.-H.;Su, W.-C.;Huang, M.-S.;Chen, Y.-M.;Chen, Chen C.-Y.;Hung, Hung H.-H.;Hu, J.-W.;Shi, J.;Zheng, W.;Rositch, A.F.;Chen, Chen C.-J.;Chatterjee, N.;Yang, P.-C.;Rothman, N.;Hsiung, C.A.;Lan, Q. |
| 國立成功大學 |
2023 |
Occupational evaluation of community-based psychiatric rehabilitation outcomes in individuals with severe mental illnesses: A ten-year retrospective study
|
Liu, Y.-C.;Yang, Yang Y.K.;Lee, Y.-C.;Lin, S.-H.;Hsu, W.-Y.;Su, W.-C.;Chen, K.C.;Lin, K.-C. |
| 國立成功大學 |
2023 |
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-na�ve, cisplatin-ineligible urothelial cancer
|
Galffy, Galffy G.;Lugowska, I.;Poddubskaya, E.V.;Cho, B.C.;Ahn, M.-J.;Han, J.-Y.;Su, W.-C.;Hauke, R.J.;Dyar, S.H.;Lee, D.H.;Serwatowski, P.;Estelles, D.L.;Holden, V.R.;Kim, Y.J.;Vladimirov, Vladimirov V.;Horvath, Z.;Ghose, A.;Goldman, A.;di, Pietro A.;Wang, J.;Murphy, D.A.;Alhadab, Alhadab A.;Laskov, M. |
| 國立成功大學 |
2023 |
Thiamet G as a Potential Treatment for Polycystic Kidney Disease
|
Su, W.-C.;Hung, C.-F.;Wang, Y.-C.;Peng, H.;Huang, W.-H.;Lo, Y.-L.;Lo, Y.-H.;Chen, Y.-C.;Su, H.-H.;Chen, Y.-L. |
| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 國立成功大學 |
2023 |
Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study
|
Chiu, Chiu C.-H.;Lin, M.-C.;Wei, Y.-F.;Chang, G.-C.;Su, W.-C.;Hsia, T.-C.;Su, J.;Wang, A.K.-F.;Jen, M.-H.;Puri, T.;Shih, J.-Y. |
| 國立成功大學 |
2023 |
Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer
|
Camidge, D.R.;Barlesi, F.;Goldman, J.W.;Morgensztern, D.;Heist, R.;Vokes, E.;Spira, A.;Angevin, E.;Su, W.-C.;Hong, D.S.;Strickler, J.H.;Motwani, Motwani M.;Dunbar, M.;Parikh, A.;Noon, E.;Blot, V.;Wu, J.;Kelly, Kelly K. |
| 國立成功大學 |
2023 |
PTPN23 ubiquitination by WDR4 suppresses EGFR and c-MET degradation to define a lung cancer therapeutic target
|
Singh, Singh S.;Yeat, N.Y.;Wang, Y.-T.;Lin, S.-Y.;Kuo, I.-Y.;Wu, K.-P.;Wang, Wang W.-J.;Wang, Wang W.-C.;Su, W.-C.;Wang, Y.-C.;Chen, R.-H. |
| 國立成功大學 |
2023 |
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
|
Tsuboi, M.;Herbst, R.S.;John, T.;Kato, T.;Majem, Majem M.;Groh�, C.;Wang, J.;Goldman, J.W.;Lu, S.;Su, W.-C.;De, Marinis F.;Shepherd, F.A.;Lee, K.H.;Le, N.T.;Dechaphunkul, A.;Kowalski, D.;Poole, L.;Bolanos, A.;Rukazenkov, Y.;Wu, Y.-L. |
| 國立成功大學 |
2023 |
Evaluation of combination treatment with DS-1205c, an AXL kinase inhibitor, and osimertinib in metastatic or unresectable EGFR-mutant non-small cell lung cancer: results from a multicenter, open-label phase 1 study
|
Yang, J.C.-H.;Su, W.-C.;Chiu, Chiu C.-H.;Shiah, H.-S.;Lee, K.-Y.;Hsia, T.-C.;Uno, M.;Crawford, N.;Terakawa, H.;Chen, W.-C.;Takayama, G.;Hsu, C.;Hong, Y.;Saintilien, C.;McGill, J.;Chang, G.-C. |
Showing items 6-15 of 419 (42 Page(s) Totally)
1 2 3 4 5 6 7 8 9 10 > >>
View [10|25|50] records per page
|
